Singapore markets open in 52 minutes
  • Straits Times Index

    3,201.89
    +10.73 (+0.34%)
     
  • S&P 500

    4,088.85
    +80.84 (+2.02%)
     
  • Dow

    32,654.59
    +431.17 (+1.34%)
     
  • Nasdaq

    11,984.52
    +321.73 (+2.76%)
     
  • BTC-USD

    30,478.84
    +586.85 (+1.96%)
     
  • CMC Crypto 200

    686.15
    +443.47 (+182.74%)
     
  • FTSE 100

    7,518.35
    +53.55 (+0.72%)
     
  • Gold

    1,813.10
    -5.80 (-0.32%)
     
  • Crude Oil

    113.80
    +1.40 (+1.25%)
     
  • 10-Yr Bond

    2.9680
    +0.0910 (+3.16%)
     
  • Nikkei

    26,659.75
    0.00 (0.00%)
     
  • Hang Seng

    20,602.52
    +652.31 (+3.27%)
     
  • FTSE Bursa Malaysia

    1,548.60
    +4.19 (+0.27%)
     
  • Jakarta Composite Index

    6,644.47
    +46.47 (+0.70%)
     
  • PSE Index

    6,594.66
    +92.54 (+1.42%)
     

Why Chemours (CC) Could Beat Earnings Estimates Again

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Chemours (CC). This company, which is in the Zacks Chemical - Diversified industry, shows potential for another earnings beat.

When looking at the last two reports, this chemical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 31.56%, on average, in the last two quarters.

For the last reported quarter, Chemours came out with earnings of $1.27 per share versus the Zacks Consensus Estimate of $0.99 per share, representing a surprise of 28.28%. For the previous quarter, the company was expected to post earnings of $0.89 per share and it actually produced earnings of $1.20 per share, delivering a surprise of 34.83%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Chemours lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Chemours currently has an Earnings ESP of +10.35%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on February 10, 2022.

When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Chemours Company (CC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting